ライフサイエンスコーパス: Stenotrophomonas maltophilia

1 ratia marcescens, Staphylococcus aureus, and Stenotrophomonas maltophilia).

2 structure of PabB from the emerging pathogen Stenotrophomonas maltophilia.

3 n Xylella fastidiosa and the human pathogen, Stenotrophomonas maltophilia.

4 he extensively drug resistant human pathogen Stenotrophomonas maltophilia.

5 talyzed by the dizinc L1 beta-lactamase from Stenotrophomonas maltophilia.

6 ermentative gram-negative bacilli, including Stenotrophomonas maltophilia.

7 nterocolitica O9, Escherichia hermannii, and Stenotrophomonas maltophilia.

8 ureus [3 methicillin-resistant S. aureus], 2 Stenotrophomonas maltophilia, 1 Klebsiella pneumoniae) a

9 losoxidans (33%), and finally, pan-resistant Stenotrophomonas maltophilia (20%).

10 scens (5.5%), Enterobacter aerogenes (4.4%), Stenotrophomonas maltophilia (4.3%), Proteus mirabilis (

11 mobacter xylosoxidans (100%) followed by MDR Stenotrophomonas maltophilia (46%), MDR Achromobacter xy

12 Staphylococcal aureus, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans

13 We sequence 552 genomes of the pathogen Stenotrophomonas maltophilia across 23 sites of the lung

14 acter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia--all major threats to our c

15 s uncommon, occurring in 2 patients with MDR Stenotrophomonas maltophilia and 2 patients with MDR Ach

16 Stenotrophomonas maltophilia and Achromobacter (Alcalige

17 (LUV) and to kill the Gram negative bacteria Stenotrophomonas maltophilia and Escherichia coli.

18 coccus spp., and the opportunistic pathogens Stenotrophomonas maltophilia and Ochrobactrum anthropi w

19 reviewed for Achromobacter xylosoxidans and Stenotrophomonas maltophilia and their antibiotic suscep

20 ction of tobramycin-resistant P. aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxi

21 s, Aeromonas caviae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Enterococcus sp.

22 Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepac

23 Standard microbiology references describe Stenotrophomonas maltophilia as oxidase negative and var

24 significantly, an extensively drug-resistant Stenotrophomonas maltophilia clinical isolate expressing

25 ta-lactamase from the opportunistic pathogen Stenotrophomonas maltophilia has been determined at 1.7

26 Stenotrophomonas maltophilia has recently emerged as an

27 patients with Achromobacter xylosoxidans and Stenotrophomonas maltophilia have similar posttransplant

28 Metallo-beta-lactamase L1 from Stenotrophomonas maltophilia is a dinuclear Zn(II) enzym

29 Stenotrophomonas maltophilia is a Gram-negative bacteriu

30 Stenotrophomonas maltophilia is a gram-negative bacteriu

31 Stenotrophomonas maltophilia is a multiple-antibiotic-re

32 Stenotrophomonas maltophilia is a ubiquitous bacterium a

33 Stenotrophomonas maltophilia is an emerging opportunisti

34 Stenotrophomonas maltophilia is an emerging, opportunist

35 The Gram-negative bacterium Stenotrophomonas maltophilia is increasingly identified

36 The L1 metallo-beta-lactamase from Stenotrophomonas maltophilia is unique among this class

37 pan-resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia, is poorly characterized.

38 seobacterium meningosepticum isolates, and 1 Stenotrophomonas maltophilia isolate) producing IMP-1, I

39 26 Acinetobacter baumannii isolates, and 11 Stenotrophomonas maltophilia isolates.

40 , Escherichia coli, Serratia marcescens, and Stenotrophomonas maltophilia isolates.

41 rized a polysaccharide lyase (Smlt1473) from Stenotrophomonas maltophilia k279a, which exhibited sign

42 c mechanism of beta-lactam hydrolysis by the Stenotrophomonas maltophilia L1 metallo-beta-lactamase.

43 ese were found to be P. aeruginosa (n = 10), Stenotrophomonas maltophilia (n = 1), and Burkholderia c

44 nt Stenotrophomonas maltophilia (n = 5), MDR Stenotrophomonas maltophilia (n = 26), and CF patients w

45 s mirabilis (n = 3), Serratia spp. (n = 10), Stenotrophomonas maltophilia (n = 43), Sphingobacterium

46 obacter xylosoxidans (n = 15), pan-resistant Stenotrophomonas maltophilia (n = 5), MDR Stenotrophomon

47 patients without Achromobacter xylosoxidans, Stenotrophomonas maltophilia or Bulkholderia cenocepacia

48 increase isolation of Burkholderia cepacia, Stenotrophomonas maltophilia, or Alcaligenes xylosoxidan

49 smid pB10 was shown to be highly unstable in Stenotrophomonas maltophilia P21 and Pseudomonas putida

50 To achieve the objective, Stenotrophomonas maltophilia strain ZL1 was used as a mo

51 rains, 5 Alcaligenes xylosoxidans strains, 5 Stenotrophomonas maltophilia strains, and 5 Pseudomonas

52 trains, 10 Pseudomonas aeruginosa strains, 8 Stenotrophomonas maltophilia strains, and 9 isolates bel

53 With the exception of Stenotrophomonas maltophilia, these organisms are infreq

54 chromosomal carbapenemases are restricted to Stenotrophomonas maltophilia, to a few Bacteroides fragi

55 ionella pneumophila, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Vibrio cholerae, and Yersi

56 3 of [corrected] 35 home-use nebulizers, and Stenotrophomonas maltophilia was isolated from 4 of 35 h

57 Stenotrophomonas maltophilia was isolated from the respi

58 trocefin with metallo-beta-lactamase L1 from Stenotrophomonas maltophilia was studied using rapid-sca

59 Stenotrophomonas maltophilia WR-C is capable of forming